PneumoNIX was selected as 1 of 15 MedTech start-ups to attend VentureWell’s investor readiness program. The program ensures the companies have a solidified go-to-market plan with planned milestones and a comprehensive due diligence deal room package. Furthermore, PneumoNIX secured partnerships to help with product launch and market adoption.
top of page
Recent Posts
See AllPneumoNIX has received follow-on Phase II grant from the NSF SBIR to continue the development of their proprietary technology.
700
PneumoNIX Medical, a Baltimore-based medtech company focused on preventing complications associated with soft tissue biopsies, announced...
210
PneumoNIX Medical was selected to present to Johns Hopkins Hospital, Maryland Department of Commerce and Technology Development...
150
bottom of page
Comentarios